top of page
  • Writer's pictureOlivia Nguyen

Celltrion’s Susbisidary Acquires Primary Care Product Assets for APAC Markets from Takeda (2020.06)

Celltrion has signed an agreement to acquire business rights several brands of Takeda Pharmaceutical for 332.4 billion won ($278.2 USD). The Deal allows Celltrion to secure patents, trademarks and sales rights for 18 prescription and over-the-counter brands in 9 markets including Thailand, Phillipines, Singapore, Malaysia, and Hong Kong. The deal marks Celltrion’s first large-scale M&A deal, giving Celltrion a gateway to strengthen its global R&D capabilities and sales channels.

1 view0 comments

Recent Posts

See All
bottom of page